Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

Sun Pharma shares are in focus after the company halted its Phase II clinical trial for SCD-044. Meanwhile, Zydus ...

In this article, we look at two stocks, one from the chemicals sector and another from the pharma sector, recommended by the Trade Brains Portal to buy for an upside potential of more than 22%. We ...

Nail Growth Support: Healthy nails grow faster when the underlying tissue is free of infection and irritation. Using Tea Tree ...

The company commissioned a 20MWp solar power project at its new facility in Kharkhoda, Haryana, and added another 10MWp solar ...

Red light therapy can help improve skin texture, wound healing, and pain. The key to success is using it consistently and ...

Benchmark equity indices Sensex and Nifty traded higher on Wednesday, tracking positive cues from global markets. Optimism ...